Mito

Valent BioSciences Announces the Retirement of Ted Melnik and Promotion of Salman Mir

Retrieved on: 
Monday, April 24, 2023

In addition, Salman Mir, currently Executive Vice President and Chief Operating Officer, has been named President and CEO, also effective July 2023.

Key Points: 
  • In addition, Salman Mir, currently Executive Vice President and Chief Operating Officer, has been named President and CEO, also effective July 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230424005639/en/
    Melnik joined Valent BioSciences in 2013 as Chief Operating Officer and was promoted to his current position in 2022.
  • Mir joined Valent BioSciences in 2012 as Vice President of Global Marketing and Business Management, where he was responsible for leading the company’s global marketing and commercial activities.
  • He returned to the U.S. in 2019 to serve as Chief Operating Officer of Valent BioSciences subsidiary Pace International LLC in Wapato, Washington.

Alfa Romeo Begins Celebrating 100th Anniversary of Quadrifoglio by Revealing New Logo

Retrieved on: 
Thursday, February 9, 2023

In particular, the centenary of Quadrifoglio has the sturdiness and elegance of the historic logo while evolving only its color point.

Key Points: 
  • In particular, the centenary of Quadrifoglio has the sturdiness and elegance of the historic logo while evolving only its color point.
  • For Autodelta's 60th anniversary, Alfa Romeo will hold a conference at the Alfa Romeo Museum in Arese, Milan, on March 5, the day the racing department was founded.
  • Stelvio, the first SUV produced by Alfa Romeo, is also at the top of the range in its Quadrifoglio version.
  • Alfa Romeo is part of the portfolio of brands offered by leading global automaker and mobility provider Stellantis.

Generational’s Mito Pereira Advances to Next Round of the PGA’s FedExCup Championship

Retrieved on: 
Wednesday, August 17, 2022

Pereira will now join 69 other top performers at the BMW Championship at the Wilmington Country Club in Delaware.

Key Points: 
  • Pereira will now join 69 other top performers at the BMW Championship at the Wilmington Country Club in Delaware.
  • Based on his St. Jude results, Pereira is now ranked 42nd , with 938 points in the latest FedExCup standings.
  • We are looking forward to the BMW Championship this weekend and will be cheering him on as he competes in the second round of the FedExCup Playoffs.
  • The FedExCup is a season-long points competition which culminates with the FedExCup Playoffs, a series of three events to determine the FedExCup champion.

Trinity Capital Inc. Provides $25 Million Growth Capital to Cepton Technologies, Inc.

Retrieved on: 
Monday, February 28, 2022

The transaction was completed prior to Cepton Technologies' closing of the merger with Growth Capital Acquisition Corp, now renamed to Cepton Inc. (Nasdaq: CPTN) ("Cepton").

Key Points: 
  • The transaction was completed prior to Cepton Technologies' closing of the merger with Growth Capital Acquisition Corp, now renamed to Cepton Inc. (Nasdaq: CPTN) ("Cepton").
  • Based in San Jose, Calif., Cepton is an innovator of lidar-based solutions for automotive (ADAS/AV), smart cities, smart spaces, and smart industrial applications.
  • The team at Cepton expects to use the loan proceeds for scaling operations to service their growing demand.
  • We are excited to support Cepton achieve its goal of deploying high performance, mass-market lidar to deliver safety and autonomy."

Stealth BioTherapeutics to Report Second Quarter Financial Results on Thursday, August 5

Retrieved on: 
Friday, July 30, 2021

BOSTON, July 30, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report second quarter 2021 financial results on Thursday, August 5, before the market opens.

Key Points: 
  • BOSTON, July 30, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report second quarter 2021 financial results on Thursday, August 5, before the market opens.
  • Management will host a conference call at8:30 am ETthat day to discuss the financial results and provide a general business update.
  • The call can be accessed by dialing (800)-908-1236 (domestic) or(212)-231-2938 (international) and referencing conference ID 13721969.
  • A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/ .

Stealth BioTherapeutics to Report First Quarter Financial Results on Tuesday, May 18, 2021

Retrieved on: 
Tuesday, May 11, 2021

b"BOSTON, May 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report first quarter 2021 financial results on Tuesday, May 18, 2021, before the market opens.\nManagement will host a conference call at8:30 am ETthat day to discuss the financial results and provide a general business update.

Key Points: 
  • b"BOSTON, May 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report first quarter 2021 financial results on Tuesday, May 18, 2021, before the market opens.\nManagement will host a conference call at8:30 am ETthat day to discuss the financial results and provide a general business update.
  • The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0921 (international) and referencing conference ID 13719019.
  • A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/ .
  • Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function.

Stealth BioTherapeutics to Report Full Year 2020 Financial Results on Tuesday, April 6, 2021

Retrieved on: 
Wednesday, March 31, 2021

BOSTON, March 31, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report full year 2020 financial results on Tuesday, April 6, 2021, before the market opens.

Key Points: 
  • BOSTON, March 31, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report full year 2020 financial results on Tuesday, April 6, 2021, before the market opens.
  • Management will host a conference call at8:30 am ETthat day to discuss the financial results and provide a general business update.
  • The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0921 (international) and referencing conference ID 13717131.
  • A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/ .

Stealth BioTherapeutics Announces Promotion of Marty Redmon to Chief Research & Development Officer

Retrieved on: 
Tuesday, March 16, 2021

BOSTON, March 16, 2021 /PRNewswire/ --Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced promotion of Marty Redmon, Ph.D., Executive Vice President, Discovery, Development, and Tech Ops, to the role of Chief Research & Development Officer, effective immediately.

Key Points: 
  • BOSTON, March 16, 2021 /PRNewswire/ --Stealth BioTherapeutics (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced promotion of Marty Redmon, Ph.D., Executive Vice President, Discovery, Development, and Tech Ops, to the role of Chief Research & Development Officer, effective immediately.
  • "Marty is an accomplished leader who has made many vital contributions to our development efforts," said Reenie McCarthy, Stealth's CEO.
  • Statements that are not historical facts, including statements about Stealth BioTherapeutics' beliefs, plans and expectations, are forward-looking statements.
  • Except as required by law, Stealth BioTherapeutics does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.